Potent in vitro Activity of SCYNEXIS’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC) May 11, 2017
SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status May 8, 2017
Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078 Apr 25, 2017
SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID Apr 21, 2017
SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Apr 12, 2017
SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request Mar 2, 2017
